Upstream Biosciences Inc. ~ Technology Overview

TECHNOLOGY OVERVIEW

Only computation can beat drug resistant mutations

Upstream has developed and streamlined an accelerated research and development process that relies upon proprietary software, strategic partnerships and cost effective testing. Our development for new treatments for diseases begins wtih a unique proprietary software. This process (patent pending) allows us to constantly generate a list of potential compounds for the treatment of specific diseases based upon historical data, ongoing industry research and feedback from testing. The compounds are prioritized by the software for likelihood of efficacy which allows us to only test the most probable candidates. The process produces a continuous stream of drug candidates and has demonstrated a one in four success rate compared to the pharmaceutical industry average of one in 10,000.

scaffolds

How it works.
Our unique, revolutionary approach to drug development involves using a proprietary discovery platform. Using historical data of disease occurrences and drug treatments, our software uses artificial intelligence and pattern recognition techniques to identify key chemical structural elements associated with their efficacy. Chemical diversity generation software is then applied to produce a family of related, potential drug candidates. Another algorithmic analysis is completed to rank the potential drug candidates based upon the known commonalities and to filter out compounds likely to be toxic. This, in turn, provides a list of high-potential, prioritized chemicals ready to be synthesized and tested by Upstream’s partners.

One of the great advantages of our proprietary technology is its ability to optimize compounds quickly and cost effectively. Feedback from experiments is added to the existing computer models — resulting in a constantly improved supply of optimized potential compounds. The technology can even be used to identify novel applications for existing drugs that are used for another disease (drug repurposing). Our technology has already generated novel compounds that, in laboratory studies, demonstrate both human and veterinary potential against major infectious diseases.

Upstream owns the worldwide rights to its existing library of novel compounds and potential drug scaffolds.

How compounds are tested.
We have entered into a number of strategic and valuable partnerships to enable us to create, test and accelerate potential drug treatments in a cost effective and efficient manner. These partnerships allow us to test multiple compounds and eliminate ineffective ones early on in the development process. By leveraging these relationships, we have access to world-class labs and industry leaders.